Xolair 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FGET5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $37,786
Award facts
- Contract value 100% obligated
- $37,786.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $37,786.40 delivery order to DMS Pharmaceutical Group Inc. for 300 mg/2 mL Xolair syringes on January 28, 2026, with completion scheduled for February 19, 2026. Xolair is a biologic immunosuppressant used to treat moderate-to-severe allergic asthma and other allergic conditions. The award is structured as a firm fixed-price delivery order with no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis. DMS Pharmaceutical Group is a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, and serves as a critical supplier within the Department of Defense pharmaceutical supply chain.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, awarded November 13, 2025, with a $499.999 billion ceiling value extending through December 31, 2036. The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to provide Department of Defense healthcare facilities worldwide with comprehensive pharmaceutical products including branded and generic prescription medications, biologics, vaccines, and medical consumables. DMS Pharmaceutical Group's established performance on numerous prior delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FGET5?
SPE2DR26FGET5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FGET5 worth?
The government has obligated $37,786 on SPE2DR26FGET5.
Is contract SPE2DR26FGET5 an order under another contract?
Yes. SPE2DR26FGET5 is a delivery order under SPE2DR25D9312, an indefinite delivery contract.
Was contract SPE2DR26FGET5 competed?
The extent of competition for SPE2DR26FGET5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award